POULTRY 
A perfect balance between safety and efficacy
Vectormune FP LT offers protection against ILT and smallpox in a single application, with a perfect balance between safety and efficacy.
Infectious laryngotracheitis (ILT)
This is a highly contagious viral respiratory disease that affects poultry and has been identified in most countries of the world. Despite efforts to control the disease through vaccination, prolonged epizootics of ILL remain a threat to the poultry industry.
Controlling infectious laryngotracheitis with conventional live vaccines has major weaknesses: the rolling infection of the vaccine virus induces aeroculitis, which would require antibiotic treatment, and slows down the growth rate of the birds. In addition, the ability of the vaccine virus to spread and its persistence in birds over a long period can cause the live vaccine to revert to virulence.
A new approach is therefore needed to control ILT using safe vaccines that do not spread.
The disease is usually referred to “Infectious Laryngotracheitis” or simply “Laryngotrachietis” (LT) in the poultry industry. ILT virus (ILTV) is a Gallid herpesvirus 1 classified as an iltvirus within the subfamily alphaherpesvirinae.
Chickens of all ages are susceptible and the viral infection will induce a life carrier state, being a latent and persistent infection with intermittent virus shedding. Stress factors will continue to be a predisposing cause for recurrent infections typical of this family of viruses.
Vectormune is available alone or in combination with AE
Vectormune® FP-LT and Vectormune® FP LT +AE have been used successfully in several countries.
Vectormune® FP-LT is a live fowlpox vector vaccine in which 2 major genes from 2 field ILT viruses have been inserted. Vectormune® FP-LT is available on the market alone or in combination with AE. When the smallpox virus replicates in the bird, it also expresses ILT proteins from the inserted genes, immunising the birds against both fowlpox and ILT. The use of fowlpox as a vector guarantees the safety and non-diffusion capacity of the ILT vaccine strain in the environment. Immunity will be strongly stimulated.
Mortality in herds vaccinated with Vectormune FP LT and those not vaccinated
In flocks vaccinated with Vectormune FP LT, mortality was 4 to 5 times lower than in previous flocks not vaccinated with Vectormune FP LT. In this case, the additional income per 1,000 pullets was €542.
Benefits of Vectormune® FP-LT vaccination in commercial broilers: improved liveability and better control of ILT infection
An epidemiological survey was carried out in 9 different companies. This survey provided data concerning: location, vaccination program and production parameters. Performance parameters were used to quantify the impact of ILT outbreaks on production, compared with normal historical data. ILT outbreaks were characterized by high morbidity and mortality in affected broiler flocks. Subcutaneous injection of Vectormune FP-LT at one day of age was one of the officially approved ILT control measures.
The results of the locks are summarized below:
Mortality rates were more than three times higher than in unvaccinated birds.
The use of Vectormune® FP-LT had a clear positive impact on the economic benefits of ILT disease prevention.
Continuous exposure to ILT in the field did not affect the performance of birds vaccinated with Vectormune® FP-LT.
